Atai Life Sciences Remains Undervalued, Analyst Initiates With Around 125% Stock Upside

What caused the collapse of US private credit firms? How will US Patriot missile aid impact Ukraine defense? Why did B&M cut profit guidance and CFO step down? What drives China's slowest GDP growth in a year? How will Kering-L’Oréal beauty deal affect luxury market? Why did the Louvre museum close after the jewel heist? What impact will Tesla's lost federal EV subsidies have?

Atai Life Sciences Remains Undervalued, Analyst Initiates With Around 125% Stock Upside

benzinga.com/analyst-stock-ratings/initiation/25/10/48184178/atai-life-sciences-remains-undervalued-analyst-initiates-with-around-125-stock-u

Needham on Monday initiated coverage on Atai Life Sciences NV (NASDAQ:ATAI), a clinical-stage biopharmaceutical company focused on developing treatments for mental health.
The company’s lead drug candidate, BPL-003, is under development for treatment-resistant depression.
• ATAI stock…

This story appeared on benzinga.com, 2025-10-13 18:21:17.